Blog

The European HealthTech landscape is currently defined by a "regulatory hardening" and a massive push for sovereign infrastructure. As we hit the middle of May 2026, the industry is transitioning from experimental AI pilots to strictly governed, clinical-grade deployments.&nbsp;Here are the major developments from this week:⚖️ The "EUDAMED" Countdown &amp; Regulatory Shifts This week marked a "data-cleansing" frenzy across the sector as the European Commission confirmed that mandatory use of the first four modules of EUDAMED (the European database on medical devices) officially begins this month.&nbsp;MDR/IVDR Integration: New guidance was finalized to govern AI medical devices under existing sectoral laws rather than separate AI legislation. This prevents manufacturers from facing redundant paperwork while ensuring "human oversight" is baked into high-risk algorithms.UK Stability: The MHRA concluded its consultation on the indefinite recognition of CE-marked devices in Great Britain. This is a huge win for EU-based startups, as it provides long-term market stability without requiring immediate UKCA marking.&nbsp; &nbsp; 🏥 Sovereign Cloud &amp; Hospital TechA significant shift toward Data Sovereignty solidified this week.AWS European Sovereign Cloud: Becton Dickinson (BD) launched its Pyxis Pro and Incada platforms using this localized infrastructure. This allows EU hospitals to scale digital tools while ensuring patient data never leaves European legal jurisdictions.NHS "Health Companion": IBM secured a £160 million contract to overhaul the NHS App. The goal is to move it beyond a simple appointment portal into a proactive "health companion" using AI to track adherence and personalised health data.&nbsp; &nbsp; 💰 Funding &amp; Strategic Investments Digital Europe Programme: The European Commission opened seven new calls worth €63.2 million. Notably, €9 million is earmarked specifically for AI-powered cancer and cardiovascular screening, while €24 million will support the European Health Data Space (EHDS) to unlock cross-border research.Impact Capital: The UK’s Eka Ventures closed a €91.5 million Fund II this week. Their focus is specifically on "unpopular" but essential areas like elderly care and regulatory-heavy HealthTech.&nbsp;Precision Medicine: Startups like 2cureX and PreComb made headlines for their work with "tumoroids" (3D lab-grown micro-tumors), signaling a massive pivot in European VC interest toward precision oncology.🤖 Clinical MilestonesSurgical Robotics: British-born CMR Surgical announced its Versius Plus platform has officially surpassed 40,000 procedures. They are currently rolling out an advanced digital analytics suite across Europe ahead of a major US expansion.Atrial Fibrillation: Following the Heart Rhythm Society meeting, J&amp;J MedTech launched the VARIPULSE Pro3in Europe. This next-gen pulsed field ablation (PFA) system is expected to significantly reduce procedure times for heart patients.Automated Suturing: The Israeli-European firm Nitinotes completed the first commercial procedures in Spain for its EndoZip™ system, the first automated suturing tool for endoscopic gastroplasty in that market.&nbsp; &nbsp; 💡 Key Takeaway The "Wild West" era of digital health pilots is over. In May 2026, success in European HealthTech is no longer just about the "shiny tool", it’s about sovereign data compliance and EUDAMED readiness.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>This week in European MedTech (mid-May 2026) is dominated by the industry's largest annual gathering in Stockholm and a high-stakes "regulatory cliff" as manufacturers race to meet new mandatory data deadlines.🇸🇪 The MedTech Forum 2026 (Stockholm) The industry's flagship event took place this week (May 11–13), serving as the primary stage for major announcements and policy debates.The "MDR Overhaul" Lobby: MedTech Europe, the leading industry body, used the forum to publish a significant position paper. They are backing the European Commission’s proposed revision of the MDR/IVDR but are demanding "targeted changes" to cut red tape. Key focus areas include innovation pathways and clearer legal integration of AI requirements.&nbsp; Sustainability Mandates: A major theme this week was the "reusable-by-default" presumption for single-use devices. Industry leaders warned that this could add unnecessary regulatory complexity without clear patient safety benefits.⏳ The EUDAMED "Hard Deadline" With less than two weeks to go, the atmosphere is "clinical-grade panic" for many SMEs.May 28 Enforcement: The European Commission confirmed that use of the first four EUDAMED modules (Actor Registration, UDI/Device Registration, Notified Bodies, and Market Surveillance) becomes mandatory on May 28, 2026.Operational Impact: Manufacturers are reporting significant bottlenecks in data validation. Companies that haven't secured their SRN (Single Registration Number) by the end of this month will effectively be locked out of the market for new product launches. 💰 Funding &amp; Strategic M&amp;A While overall VC volume is slightly down compared to last year, the "average deal size" has increased, showing a shift toward late-stage, proven winners.The "Mega-Round" Era: Recent data discussed at the Forum shows a "winner-takes-most" environment. Key recent deals include Oviva ($235M) and DentalMonitoring ($100M).Sovereign Infrastructure: There is a massive uptick in investment for sovereign cloud solutions (like the AWS European Sovereign Cloud) to host MedTech data, ensuring compliance with both GDPR and the evolving European Health Data Space (EHDS) rules.🇬🇧 UK Regulatory Divergence (or lack thereof) Across the Channel, the MHRA is finishing its final week of review regarding the indefinite recognition of CE-marked devices in Great Britain.The "Reliance" Strategy: The UK government confirmed it will introduce a "statutory instrument" later this year to formalize an international reliance scheme. This would allow devices approved by "comparable regulators" (like the EU or FDA) to bypass redundant UK-specific testing, a major relief for European exporters.🏥 Tech Spotlight: "Electric Medicine" A breakout trend highlighted this week is the expansion of Bioelectronic Medicine. We are seeing a shift from traditional pacemakers to non-invasive neuromodulation devices for chronic pain and mental health, with several Nordic startups presenting clinical trial data for "Brain-Computer Interfaces" (BCI) that use non-surgical sensors.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

This Week in European MedTech and HealthTech: 15th May 2026

The report from the King’s College London Policy Institute, titled "The Use of AI in Healthcare" (and related studies by the KCL Institute for AI), outlines the current landscape of artificial intelligence within the NHS and the broader UK health sector.Below are 10 key points summarised from the report and its findings:1) Rise of "Self-Diagnosis" via AI: One in seven people (15%) have used AI chatbots for health advice instead of contacting a GP. The primary drivers are convenience (46%), curiosity (45%), and uncertainty about whether their health concern is serious enough for a doctor. 2) Mental Health Support Gap: Approximately 10% of the public have used AI for mental health therapy or wellbeing support instead of seeing a trained professional. While 53% of users found it helpful, 42% of the general public still believe AI is "bad" for mental health overall. 3) Efficiency in Diagnostics: Clinical trials (specifically in sonography) found that AI-assisted scans could identify abnormalities almost twice as quickly (reducing scan time by over 40%) without sacrificing accuracy, allowing staff to spend more time on direct patient communication. 4) Public Demand for Regulation: Three-quarters (76%) of the public believe AI tools in patient care should be officially approved and regulated, even if this slows down their adoption. There is a clear consensus that "doctors should not be able to choose AI tools freely" without oversight. 5) Desire for Opt-Out Rights: Majorities of the public (58–63%) believe they should be informed in advance if AI is being used for reading test results, reviewing X-rays, or deciding queue priority, and should have the right to opt out of its use. 6) Accountability Concerns: When AI makes an error (e.g., missing a problem in a clinical image), 34% of the public believe the doctor using the tool should be held responsible, while 24% believe the NHS Trust is accountable. Only 6% would primarily blame the company that developed the AI. 7) Data Privacy vs. Training: Public comfort with data sharing is conditional. 47% feel uncomfortable with their records being used to train AI if the data identifies them personally, but comfort increases significantly if the data is anonymized. 8) Digital Maturity Gap: While 86% of NHS organizations have electronic patient records, only 20% are considered "digitally mature" enough to scale AI effectively. Infrastructure issues like poor Wi-Fi and outdated hardware remain significant "blockers." 9) Workforce Anxiety: While 76% of NHS staff support using AI for care, 65% worry that AI will make them feel more distant from patients. There is a "tech novice" gap in the workforce that requires significant upskilling and training.10) Funding Challenges: Funding remains the top barrier to transformation. Recent cuts to the NHS AI Lab budget (from £250 million to £139 million) have complicated the ability to scale AI initiatives beyond the pilot phase.Source: <a href="https://www.kcl.ac.uk/policy-institute/assets/use-of-ai-in-healthcare.pdf">https://www.kcl.ac.uk/policy-institute/assets/use-of-ai-in-healthcare.pdf</a>

10 Key Takeaways from the King’s College London Policy Institute "The Use of AI in Healthcare" report

The landscape of healthcare technology and digital health equity markets from late 2024 through mid-2026 has been characterised by a structural revaluation that industry analysts define as the emergence of "Health Tech 2.0". This transition represents a definitive pivot away from the speculative, growth-at-all-costs models of the 2015 to 2021 era, frequently termed Health Tech 1.0, which were often defined by poor unit economics and a reliance on pandemic-driven temporary tailwinds.&nbsp; &nbsp;&nbsp; The new cohort of companies that have entered the public markets in the last 12 to 24 months, including Tempus AI, Waystar, Caris Life Sciences, Hinge Health, Omada Health and Kestra Medical, are distinguished by significantly more robust business metrics, including a clear path to profitability, deeply embedded artificial intelligence infrastructure and clinical-grade evidence that justifies their inclusion in standard medical workflows. &nbsp;&nbsp; The collective performance of these stocks in 2025 demonstrated a "comeback story" for the sector, with the Health Tech 2.0 cohort adding approximately $36.6 Billion in fresh market capitalisation. This cohort rose by an average of 18% during 2025, matching the gains of the S&amp;P 500 and the NASDAQ Composite, and notably eclipsing the 7% decline observed in the Nasdaq Emerging Cloud Index.&nbsp; &nbsp;&nbsp; However, as the market progressed into the first half of 2026, the performance of individual entities within this group became highly bifurcated. Investors began to differentiate between companies achieving "Infrastructure Grade" status, those with high net revenue retention and software like margins and those facing traditional healthcare service headwinds or valuation compression due to lingering skepticism from previous market cycles.Future Outlook: Healthtech Infrastructure in late 2026 &nbsp;&nbsp; The strategic focus for digital health in the second half of 2026 is shifting from "experimentation" to "infrastructure". The winners of this next phase will be companies that resemble utilities: trusted pipes, models, and reimbursement mechanisms that are deeply embedded into the healthcare system. &nbsp;&nbsp; Key Predictions for the 2026/2027 Cycle &nbsp;&nbsp; Clinical-Grade Wearables: Consumer health data is becoming clinical-grade, as wearables are pulled into regulated workflows and procurement frameworks (e.g., Kestra Medical's integration into hospital WCD protocols).GLP-1 Stability: The initial hype around obesity medications is giving way to a focus on durable outcomes. Companies like Omada Health that pair medication with lifestyle coaching will be rewarded for long-term adherence metrics.AI ROI Mandate: By the end of 2026, AI will no longer be treated as a pilot. Hospitals and payers will expect a positive ROI for all AI applications, and those unable to provide tangible evidence of cost savings or clinical throughput will face valuation compression.M&amp;A Consolidation: The "patent cliff" and favoUrable antitrust environment will likely lead to a series of high-value acquisitions in the oncology (Tempus/Caris) and MSK (Hinge) segments.&nbsp;In summary, the share prices of the digital health and healthtech companies that have IPOed in the last 12-18 months reflect a broader market rebalancing.&nbsp; &nbsp;&nbsp; While Hinge Health and Tempus AI represent the high-margin, data-rich winners of the current cycle, the operational progress at Waystar, Omada Health and Caris Life Sciences suggests that the valuation gap between "Health Tech 2.0" and the broader technology market is likely to close as these firms prove their durability in a complex regulatory and economic landscape.&nbsp; &nbsp;&nbsp; The sector's transition from speculative innovation to infrastructure-grade performance marks a structural turning point that promises to redefine the financial and clinical standards of the healthcare industry for the next decade.Click here to read the report in full <a href="https://www.healthcare.digital/single-post/digital-health-and-healthtech-ipo-performances-in-the-last-12-months-tempus-ai-waystar-caris-life">https://www.healthcare.digital/single-post/digital-health-and-healthtech-ipo-performances-in-the-last-12-months-tempus-ai-waystar-caris-life</a>

Digital Health and HealthTech IPO Performances in the last 12 months: Tempus AI, Waystar, Caris Life Sciences, Hinge Health, Omada Health, Kestra Medical

The acquisition of Optum UK, encompassing the EMIS Group, by the global alternative asset management firm TPG in March 2026, marks the beginning of a decisive era for the United Kingdom’s primary care technology landscape. This transition, occurring less than three years after UnitedHealth Group’s initial purchase of EMIS, signifies a fundamental shift in the stewardship of the data infrastructure supporting over half of the general practices in England.&nbsp; &nbsp;&nbsp; As the NHS navigates a pivotal "analogue to digital" transition defined by the 10-Year Health Plan, the strategic trajectory of EMIS under private equity ownership will be characterised by the aggressive modernisation of its cloud-native platform, EMIS-X and the integration of sophisticated artificial intelligence tools designed to mitigate a systemic workforce crisis.&nbsp; &nbsp;&nbsp; This transformation is set against a backdrop of intensifying competition from European entrants like Doctolib and a complex geopolitical and professional debate regarding data sovereignty and the role of the Federated Data Platform (FDP).Conclusions and Strategic Recommendations &nbsp;&nbsp; The acquisition of Optum UK and EMIS by TPG represents a high-stakes bet on the digital maturity of the UK’s primary care sector. For TPG, the challenge is to transform a legacy incumbent into a cloud-native, AI-first platform without alienating a disillusioned clinical workforce or falling foul of an increasingly protectionist data governance environment. &nbsp;&nbsp; For the NHS and Integrated Care Boards (ICBs), the next two years represent a window of opportunity to leverage TPG’s investment capacity to solve the "admin burden" crisis. However, the "left shift" of care into the community cannot succeed if the underlying IT infrastructure remains a source of "click fatigue" and administrative delay. &nbsp;&nbsp; The emergence of cloud-native competitors like Medicus/Doctolib indicates that the era of the "uncontested duopoly" is over. To maintain its market-leading position, EMIS must ensure that EMIS-X delivers the promised 70% productivity gains while maintaining the "trusted system" status that has defined the brand for decades. The success of this venture will ultimately be measured not just by financial returns for TPG investors, but by the ability of 4,000 GP practices to provide safe, integrated, and timely care to a population that is increasingly digitally demanding yet profoundly concerned about the stewardship of its most sensitive data. &nbsp;&nbsp; The integration of the Federated Data Platform, the rollout of ambient AI and the migration to EMIS-X represent a triple-helix of technological change that will redefine British general practice by 2028. In this volatile landscape, the "human-in-the-loop" principle and the preservation of clinician-as-data-controller will be the essential prerequisites for the successful digitalisation of the frontline.Click here to read the report in full <a href="https://www.healthcare.digital/single-post/the-strategic-transformation-of-uk-primary-care-digital-infrastructure-tpg-s-acquisition-of-emis-an" data-mce-href="https://www.healthcare.digital/single-post/the-strategic-transformation-of-uk-primary-care-digital-infrastructure-tpg-s-acquisition-of-emis-an">https://www.healthcare.digital/single-post/the-strategic-transformation-of-uk-primary-care-digital-infrastructure-tpg-s-acquisition-of-emis-an</a>

TPG’s Acquisition of EMIS and The Strategic Transformation of UK Primary Care Digital Infrastructure

The global health technology sector has entered a transformative phase characterised by the convergence of continuous biometric monitoring, generative artificial intelligence, and synchronous clinical care. This paradigm shift is most prominently evidenced by the recent strategic expansion of WHOOP, a human performance company that has historically focused on the optimisation of elite athletic performance but is now aggressively repositioning itself as a clinical-grade "Health Operating System".&nbsp; The introduction of on-demand telehealth services, advanced electronic health record (EHR) synchronisation, and a persistent AI context layer represents a direct challenge to the legacy model of episodic, snapshot-based healthcare. By bridging the gap between passive sensor data and active medical intervention, the industry is witnessing the maturation of the "quantified self" movement into a formal component of the healthcare continuum.Conclusion: The Future of the Quantified Self &nbsp;&nbsp; The transformation of the wearable fitness tracker into a clinical health platform marks a decisive shift in how individuals and the medical community interact with personal health data. The integration of synchronous telehealth, generative AI, and EHR synchronisation suggests that the "Quantified Self" movement is graduating from a hobbyist pursuit to a formal medical utility. &nbsp;&nbsp; The architectural shift from reactive monitoring to proactive guidance, facilitated by the "My Memory" framework and the clinical interpretation of longitudinal biometrics, addresses the long-standing criticism that wearables provide data without context. By positioning the AI as a "physician’s assistant" rather than a replacement for human medical expertise, the company is navigating a middle path that balances the efficiency of algorithms with the accountability of medical licensing. &nbsp;&nbsp; However, the path forward is fraught with regulatory and legal risks. The standoff with the FDA and the ongoing privacy class actions underscore the vulnerability of health tech companies operating in the "regulatory gap" between consumer gadgets and regulated medical devices. Furthermore, the aggressive competition from Google and the Fitbit Air suggests a period of intense pricing pressure that may force a choice between high-touch human care and affordable algorithmic health. &nbsp;&nbsp; As the company moves toward an anticipated IPO in 2026, its ability to maintain high standards of data security while scaling its clinical offerings will be the ultimate determinant of its long-term viability. The evolution of the platform from a "strap" to a "Health Operating System" represents a gamble that the future of medicine is continuous, conversational, and deeply personalized. The success of this model will likely establish the blueprint for the next generation of digital health ecosystems worldwide.Please click here to read the full report <a href="https://www.healthcare.digital/single-post/whoop-and-the-future-of-the-quantified-self">https://www.healthcare.digital/single-post/whoop-and-the-future-of-the-quantified-self</a>

Whoop and the Future of the Quantified Self

The healthcare industry in 2026 has transitioned from a period of experimental artificial intelligence fervour to a phase of rigorous industrialisation, where the value of technology is measured by its ability to stabilise margins and secure sensitive data rather than its capacity for high-profile public spectacle. International Business Machines (IBM), having navigated a decade of volatility in its Watson Health division, has executed a profound strategic re-entry into the sector. &nbsp;&nbsp; This shift is defined by a move away from being the clinical "face" of healthcare AI, once epitomised by the Jeopardy winning Watson, toward becoming the "neutral plumbing" of the industry: the secure, hybrid-cloud infrastructure foundation that enables hospitals to run their AI ecosystems with verifiable safety and predictive economics.&nbsp; &nbsp;&nbsp; In a climate defined by severe workforce shortages and acute margin pressure, hospitals are increasingly rejecting monolithic, proprietary "black box" solutions in favour of open, interoperable platforms that prioritise backend efficiency and data sovereignty.Conclusions &nbsp;&nbsp; The re-emergence of IBM in the healthcare sector in 2026 is defined by a rigorous focus on "Efficiency" and the provision of a secure, hybrid-cloud foundation. By abandoning the high-risk endeavor of clinical tool development and doubling down on "neutral plumbing," IBM has addressed the specific pain points of a cash-strapped industry: margin pressure, workforce shortages, and regulatory uncertainty. The transition from "Jeopardy!" to "Efficiency" is a strategic acknowledgement that in a highly regulated, high-stakes domain like medicine, the most valuable technology is the one that operates reliably in the background, securing the data and automating the administrative toil that has long hindered the progress of digital healthcare.&nbsp; &nbsp;&nbsp; Strategic success for health systems in the next three years will be determined by their ability to treat AI not as a science project, but as core infrastructure. IBM’s blueprint for the AI Operating Model provides the necessary framework for this transition, offering hospitals the "peace of mind" required to scale AI safely and responsibly in the industrial era of medicine.Please click here to read the full report <a href="https://www.healthcare.digital/single-post/ibm-is-re-entering-the-healthcare-space-less-jeopardy-and-more-efficiency">https://www.healthcare.digital/single-post/ibm-is-re-entering-the-healthcare-space-less-jeopardy-and-more-efficiency</a>

Nelson Advisors

Blog

This Week in European MedTech and HealthTech: 15th May 2026

10 Key Takeaways from the King’s College London Policy In...

Digital Health and HealthTech IPO Performances in the las...

TPG’s Acquisition of EMIS and The Strategic Transformatio...

Whoop and the Future of the Quantified Self

IBM is re-entering the healthcare space: Less "Jeopardy!"...